FDA Approves Praxbind < sup > ® < /sup > (idarucizumab), Specific Reversal Agent for Pradaxa < sup > ® < /sup > (dabigatran etexilate)

FDA Approves Praxbind < sup > ® < /sup > (idarucizumab), Specific Reversal Agent for Pradaxa < sup > ® < /sup > (dabigatran etexilate)

Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news